Related Experiment Videos
Current perspectives in muscle invasive bladder cancer
1Vincenzo Pansadoro Foundation, Clinic Pio XI, Via Aurelia 559, 00165, Rome, Italy. cstern@mclink.it
European Journal of Cancer (Oxford, England : 1990)
|March 2, 2002
Summary
Muscle-infiltrating bladder cancer requires a multidisciplinary approach. Research is ongoing to determine if adjuvant chemotherapy after cystectomy improves survival for these patients.
Area of Science:
- Oncology
- Urology
Background:
- Muscle-infiltrating bladder cancer (MIBC) necessitates a collaborative, multimodal treatment strategy involving urologists, medical oncologists, and radiotherapists.
- Neoadjuvant chemotherapy has not definitively improved survival in MIBC but may aid bladder preservation programs.
- Patient response to neoadjuvant chemotherapy (e.g., M-VAC) is a significant prognostic indicator, potentially reflecting patient selection.
Purpose of the Study:
- To investigate the optimal timing of chemotherapy administration in muscle-infiltrating bladder cancer: neoadjuvant versus adjuvant settings.
- To clarify whether immediate adjuvant chemotherapy following cystectomy enhances survival rates in MIBC patients.
Main Methods:
- The study references the EORTC (European Organisation for Research and Treatment of Cancer) protocol 30994, an international trial investigating adjuvant chemotherapy.
- The trial aims to address unresolved questions regarding the efficacy of adjuvant chemotherapy post-cystectomy.
Main Results:
- The definitive results of the EORTC protocol 30994 are pending, which are expected to provide clarity on the study's objectives.
- Current understanding suggests neoadjuvant chemotherapy response is prognostic, but its role in improving overall survival remains under investigation.
Conclusions:
- The optimal role and timing of chemotherapy in the management of muscle-infiltrating bladder cancer are still being determined.
- Further research, particularly through trials like EORTC 30994, is crucial to establish evidence-based guidelines for adjuvant chemotherapy in MIBC.